Acumen Pharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Acumen Pharmaceuticals, Inc. - overview
Established
1996
Location
Charlottesville, VA, US
Primary Industry
Biotechnology
About
Based in Virginia, US, and founded in 1996 by Grant A. Krafft, Acumen Pharmaceuticals, Inc. aka Acumen, operates as a research and drug development company providing treatment solutions for Alzheimer’s disease by helping in reducing soluble oligomers of the amyloid-beta peptide in Alzheimer's disease. The company is a publicly-traded company on NASDAQ by the ticker name of ABOS.
As of March 2022, the employee count was 17 and As of Dec 2020, the revenue was 10. 4 Million. In April 2013, Acumen Pharmaceuticals, Inc. raised USD 20 million in series A funding led by BFV Partners, with participation from Glynn Capital and Praxis Technologies, NeuroVentures also participated in the round.
The company offers ACU193 as an anti-amyloid-beta oligomer (AβO) monoclonal antibody (mAb) and prevents toxic ABOs from binding to dendritic spines thereby perving neural function. ACU193 was a research development between Acumen and Merck.
Current Investors
NeuroVentures
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Mental Health Services
Website
www.acumenpharm.com
Verticals
HealthTech
Total Amount Raised
Subscriber access only
Acumen Pharmaceuticals, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IPO | Completed | Acumen Pharmaceuticals, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.